期刊
CURRENT MEDICINAL CHEMISTRY
卷 13, 期 13, 页码 1567-1584出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986706777442011
关键词
alpha 7 neuronal nicotinic acetylcholine receptors (nAChRs); alpha 7 selective nicotinic ligand; quinuclidine; allosteric modulator; radiolabeled imaging ligand
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand gated ion channels of broad distribution and structural heterogeneity. Their functional diversity demonstrated involvement in a variety of neuronal processes (e.g., sensory gating and cognitive function) and generated great interest in them as targets for therapeutic intervention in a number of neuropathological conditions and diseases. In order to control distinct nicotinic functions pharmacologically, it is important to design ligands that selectively interact with distinct receptor subtypes in such a way as to maximize the therapeutic effect and minimize the adverse effects. The alpha 7 nAChR. a CNS subtype, has been the most intensively studied nAChR in recent years. Selective alpha 7 nAChR agonists have been developed as potential candidates for the treatment of schizophrenia, cognitive disorders (including Alzheimer's disease), and inflammation. Despite early concerns that the rapid desensitization property of the alpha 7 nAChR would limit their therapeutic potential, several have already been advanced to clinical trials (e.g., PH-399733, Pfizer; MEM 3454, Memory Pharmaceuticals/Roche). Further development of allosteric modulators and pharmaceutically relevant antagonists might expand the therapeutic potential of compounds that target alpha 7 nAChRs. In this review we briefly describe the structure and function of the alpha 7 nAChR and its in vitro and in vivo pharmacology, discuss the clinical relevance of these efforts, and review the current progress in alpha 7 ligand development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据